Revisiting the bioavailability of flavan-3-ols in humans: A systematic review and comprehensive data analysis
Reviewartikel, 2023

This systematic review summarizes findings from human studies investigating the different routes of absorption, metabolism, distribution and excretion (ADME) of dietary flavan-3-ols and their circulating metabolites in healthy subjects. Literature searches were performed in PubMed, Scopus and the Web of Science. Human intervention studies using single and/or multiple intake of flavan-3-ols from food, extracts, and pure compounds were included. Forty-nine human intervention studies met inclusion criteria. Up to 180 metabolites were quantified from blood and urine samples following intake of flavan-3-ols, mainly as phase 2 conjugates of microbial catabolites (n = 97), with phenyl-γ-valerolactones being the most representative ones (n = 34). Phase 2 conjugates of monomers and phenyl-γ-valerolactones, the main compounds in both plasma and urine, reached two peak plasma concentrations (Cmax) of 260 and 88 nmol/L at 1.8 and 5.3 h (Tmax) after flavan-3-ol intake. They contributed to the bioavailability of flavan-3-ols for over 20%. Mean bioavailability for flavan-3-ols was moderate (31 ± 23%, n bioavailability values = 20), and it seems to be scarcely affected by the amount of ingested compounds. While intra- and inter-source differences in flavan-3-ol bioavailability emerged, mean flavan-3-ol bioavailability was 82% (n = 1) and 63% (n = 2) after (−)-epicatechin and nut (hazelnuts, almonds) intake, respectively, followed by 25% after consumption of tea (n = 7), cocoa (n = 5), apples (n = 3) and grape (n = 2). This highlights the need to better clarify the metabolic yield with which monomer flavan-3-ols and proanthocyanidins are metabolized in humans. This work clarified in a comprehensive way for the first time the ADME of a (poly)phenol family, highlighting the pool of circulating compounds that might be determinants of the putative beneficial effects linked to flavan-3-ol intake. Lastly, methodological inputs for implementing well-designed human and experimental model studies were provided.

Phenyl-γ-valerolactones

Phenolics

(Poly)phenols

Metabolites

Pharmacokinetics

Excretion

Författare

Giuseppe Di Pede

Universita degli Studi di Parma

Pedro Mena

Universita degli Studi di Parma

Letizia Bresciani

Universita degli Studi di Parma

Mariem Achour

Université Clermont Auvergne

Rosa M. Lamuela-Raventós

Universitat de Barcelona

Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición

Ramon Estruch

Universitat de Barcelona

Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición

Rikard Landberg

Chalmers, Life sciences, Livsmedelsvetenskap

Sabine E. Kulling

Max Rubner-Institut, Germany

David S. Wishart

University of Alberta

Ana Rodriguez-Mateos

King's College London

Alan Crozier

King Saud University

School of Medicine, Dentistry & Nursing

Claudine Manach

Université Clermont Auvergne

Daniele Del Rio

Universita degli Studi di Parma

Molecular Aspects of Medicine

0098-2997 (ISSN) 18729452 (eISSN)

Vol. 89 101146

Bioaktiva ämnen i maten har betydelse för kardiometabol hälsa

Formas (2019-02201), 2019-12-01 -- 2022-12-31.

Ämneskategorier

Farmaceutisk vetenskap

Livsmedelsvetenskap

Näringslära

DOI

10.1016/j.mam.2022.101146

PubMed

36207170

Mer information

Senast uppdaterat

2023-01-30